Splenectomy in plasma cell dyscrasias

A review of the clinical practice

Prashant Kapoor, Ekta Kapoor, Priya Radhakrishnan, Paulette Mehta

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Plasma cell dyscrasias are a group of clinically and biochemically diverse disorders of unknown etiology, characterized by the disproportionate proliferation of one or more clones of B cells, and the presence of a structurally and electrophoretically homogeneous (monoclonal) immunoglobulin or polypeptide subunit in serum or urine. The role of splenectomy in the management of plasma cell dyscrasias has not been well defined. Using MEDLINE, the authors searched the English-language published literature from the year 1970 through September 2005 to determine the indications for splenectomy in plasma cell dyscrasias. A review of the literature in humans and animals supported the idea that the spleen provides a special microenvironment favorable for homing or differentiation of IgM producing B cells, and splenectomy can, at times, lead to remission in Waldenström's macroglobulinemia. The other reported reasons for splenectomy in plasma cell dyscrasias are hypersplenism-related pancytopenia, control of splenic plasmacytomas, and management of a splenic abscess. Splenic infiltration in primary amyloidosis can be an indication for splenectomy, where removal of a large spleen can also reverse an acquired factor X deficiency. Thus, the spleen can be considered a potential target organ for management of plasma cell dyscrasias, and therapeutic success has been achieved with removal of this organ. However, splenectomy can be a potentially morbid procedure in patients with plasma cell dyscrasias, and major postoperative complications include infection, hemorrhage, and thrombosis.

Original languageEnglish (US)
Pages (from-to)946-954
Number of pages9
JournalAmerican Journal of Hematology
Volume81
Issue number12
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Paraproteinemias
Splenectomy
Spleen
Factor X Deficiency
B-Lymphocytes
Hypersplenism
Waldenstrom Macroglobulinemia
Pancytopenia
Plasmacytoma
MEDLINE
Abscess
Immunoglobulin M
Immunoglobulins
Thrombosis
Language
Clone Cells
Urine
Hemorrhage
Peptides
Infection

Keywords

  • AL amyloidosis
  • Factor X deficiency
  • Multiple myeloma
  • Plasmacytomas
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Hematology

Cite this

Splenectomy in plasma cell dyscrasias : A review of the clinical practice. / Kapoor, Prashant; Kapoor, Ekta; Radhakrishnan, Priya; Mehta, Paulette.

In: American Journal of Hematology, Vol. 81, No. 12, 01.12.2006, p. 946-954.

Research output: Contribution to journalReview article

@article{6b2cbe3367144309aa6ca848d3625d6e,
title = "Splenectomy in plasma cell dyscrasias: A review of the clinical practice",
abstract = "Plasma cell dyscrasias are a group of clinically and biochemically diverse disorders of unknown etiology, characterized by the disproportionate proliferation of one or more clones of B cells, and the presence of a structurally and electrophoretically homogeneous (monoclonal) immunoglobulin or polypeptide subunit in serum or urine. The role of splenectomy in the management of plasma cell dyscrasias has not been well defined. Using MEDLINE, the authors searched the English-language published literature from the year 1970 through September 2005 to determine the indications for splenectomy in plasma cell dyscrasias. A review of the literature in humans and animals supported the idea that the spleen provides a special microenvironment favorable for homing or differentiation of IgM producing B cells, and splenectomy can, at times, lead to remission in Waldenstr{\"o}m's macroglobulinemia. The other reported reasons for splenectomy in plasma cell dyscrasias are hypersplenism-related pancytopenia, control of splenic plasmacytomas, and management of a splenic abscess. Splenic infiltration in primary amyloidosis can be an indication for splenectomy, where removal of a large spleen can also reverse an acquired factor X deficiency. Thus, the spleen can be considered a potential target organ for management of plasma cell dyscrasias, and therapeutic success has been achieved with removal of this organ. However, splenectomy can be a potentially morbid procedure in patients with plasma cell dyscrasias, and major postoperative complications include infection, hemorrhage, and thrombosis.",
keywords = "AL amyloidosis, Factor X deficiency, Multiple myeloma, Plasmacytomas, Waldenstr{\"o}m's macroglobulinemia",
author = "Prashant Kapoor and Ekta Kapoor and Priya Radhakrishnan and Paulette Mehta",
year = "2006",
month = "12",
day = "1",
doi = "10.1002/ajh.20736",
language = "English (US)",
volume = "81",
pages = "946--954",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Splenectomy in plasma cell dyscrasias

T2 - A review of the clinical practice

AU - Kapoor, Prashant

AU - Kapoor, Ekta

AU - Radhakrishnan, Priya

AU - Mehta, Paulette

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Plasma cell dyscrasias are a group of clinically and biochemically diverse disorders of unknown etiology, characterized by the disproportionate proliferation of one or more clones of B cells, and the presence of a structurally and electrophoretically homogeneous (monoclonal) immunoglobulin or polypeptide subunit in serum or urine. The role of splenectomy in the management of plasma cell dyscrasias has not been well defined. Using MEDLINE, the authors searched the English-language published literature from the year 1970 through September 2005 to determine the indications for splenectomy in plasma cell dyscrasias. A review of the literature in humans and animals supported the idea that the spleen provides a special microenvironment favorable for homing or differentiation of IgM producing B cells, and splenectomy can, at times, lead to remission in Waldenström's macroglobulinemia. The other reported reasons for splenectomy in plasma cell dyscrasias are hypersplenism-related pancytopenia, control of splenic plasmacytomas, and management of a splenic abscess. Splenic infiltration in primary amyloidosis can be an indication for splenectomy, where removal of a large spleen can also reverse an acquired factor X deficiency. Thus, the spleen can be considered a potential target organ for management of plasma cell dyscrasias, and therapeutic success has been achieved with removal of this organ. However, splenectomy can be a potentially morbid procedure in patients with plasma cell dyscrasias, and major postoperative complications include infection, hemorrhage, and thrombosis.

AB - Plasma cell dyscrasias are a group of clinically and biochemically diverse disorders of unknown etiology, characterized by the disproportionate proliferation of one or more clones of B cells, and the presence of a structurally and electrophoretically homogeneous (monoclonal) immunoglobulin or polypeptide subunit in serum or urine. The role of splenectomy in the management of plasma cell dyscrasias has not been well defined. Using MEDLINE, the authors searched the English-language published literature from the year 1970 through September 2005 to determine the indications for splenectomy in plasma cell dyscrasias. A review of the literature in humans and animals supported the idea that the spleen provides a special microenvironment favorable for homing or differentiation of IgM producing B cells, and splenectomy can, at times, lead to remission in Waldenström's macroglobulinemia. The other reported reasons for splenectomy in plasma cell dyscrasias are hypersplenism-related pancytopenia, control of splenic plasmacytomas, and management of a splenic abscess. Splenic infiltration in primary amyloidosis can be an indication for splenectomy, where removal of a large spleen can also reverse an acquired factor X deficiency. Thus, the spleen can be considered a potential target organ for management of plasma cell dyscrasias, and therapeutic success has been achieved with removal of this organ. However, splenectomy can be a potentially morbid procedure in patients with plasma cell dyscrasias, and major postoperative complications include infection, hemorrhage, and thrombosis.

KW - AL amyloidosis

KW - Factor X deficiency

KW - Multiple myeloma

KW - Plasmacytomas

KW - Waldenström's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=33845274932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845274932&partnerID=8YFLogxK

U2 - 10.1002/ajh.20736

DO - 10.1002/ajh.20736

M3 - Review article

VL - 81

SP - 946

EP - 954

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -